← Back

Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Price · split & dividend adjusted
News & notes moving JBIO
Biotech & Genomic Medicine▼

Jade Biosciences reports wider Q2 loss, expects autoimmune pipeline interim data in 2027

Jade Biosciences reported a wider net loss for the second quarter ended June 30, 2026, and provided updates on its autoimmune pipeline, with interim data from multiple programs expected in 2027. The net loss widened to $55.76 million, or $0.76 per share, from $32.13 million, or $0.86 per share, a year earlier, as research and development expenses more than doubled to $50.06 million and general and administrative costs rose to $8.85 million. The company held $461.20 million in cash, cash equivalents and investments as of June 30, 2026, which it expects to fund operations into the fourth quarter of 2028, supported by a $172.5 million public offering. Jade has initiated the Phase 2 JUNIPER trial for JADE101 in IgA nephropathy, with interim data expected in 2027, and plans a registrational Phase 3 trial in the first half of 2027. Dosing has begun in a Phase 1 trial of JADE201 for rheumatoid arthritis, with biomarker-rich interim data expected in 2027, while JADE301 for dermatomyositis is set to enter a Phase 1 trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.
JBIO ▼
Biotech & Genomic Medicine
RTTNews·16dRead more ▾
Biotech & Genomic Medicine▲

UBS Initiates Jade Biosciences with Buy Rating and $45 Price Target

UBS initiated coverage of Jade Biosciences with a Buy rating and a $45 price target, citing its lead program JADE101 as a potential best-in-class therapy in the $20 billion IgA nephropathy market. The firm estimates JADE101 could reach peak sales of approximately $3 billion to $4 billion and believes the market can support multiple successful treatments. Earlier this month, Jade Biosciences reported positive interim Phase 1 results for JADE101, showing roughly 70% reductions in IgA levels sustained through 12 weeks at the 700 mg dose, along with strong APRIL suppression and a favorable safety profile. The company has advanced JADE101 into Phase 2 development and plans a Phase 3 trial in the first half of 2027.
JBIO ▲
Biotech & Genomic Medicine
Insider Monkey·57dRead more ▾
Biotech & Genomic Medicine▲

Boundless Bio, Monopar, Galectin Lead Biotech Gainers on Pipeline Advances

Several biotech stocks surged on Tuesday, led by Boundless Bio which agreed to an all-stock merger with privately held Serapha Bio. Boundless Bio expects to declare a cash dividend to pre-merger stockholders before the deal closes in the fourth quarter of 2026, after which the combined company will operate as Serapha Bio and trade on Nasdaq under the ticker AATD. Monopar Therapeutics rose over 19% with its New Drug Application for ALXN1840 in Wilson disease on track for mid-2026 submission to the FDA. Galectin Therapeutics gained over 11% after reaching an agreement with the FDA on key elements of its planned Phase 3 program for Belapectin in MASH cirrhosis with portal hypertension, with the final protocol expected in the third quarter of 2026. Other notable movers included Jade Biosciences, up nearly 13% amid progress in its autoimmune pipeline, and Treace Medical Concepts, up almost 12% following the first surgical use of its HyperPlate XM implant.
BOLD ▲GALT ▲JBIO ▲MNPR ▲TMCI ▲
Biotech & Genomic Medicine ▲
RTTNews·64dRead more ▾
© 2026 MarketDXAsset